Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of less than 2 years using serum specimens
Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Cognitive impairment/encephalopathy
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency), or multiple sclerosis
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without obvious cause, especially in a patient with past or family history of cancer
-A rising autoantibody titer in a previously seropositive patient suggests cancer recurrence
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AEPSI | Epilepsy, Interpretation, S | No | Yes |
GANG | AChR Ganglionic Neuronal Ab, S | No | Yes |
AMPCS | AMPA-R Ab CBA, S | No | Yes |
AMPHS | Amphiphysin Ab, S | No | Yes |
AGN1S | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
ANN2S | Anti-Neuronal Nuclear Ab, Type 2 | No | Yes |
ANN3S | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
CS2CS | CASPR2-IgG CBA, S | No | Yes |
CRMS | CRMP-5-IgG, S | No | Yes |
DPPIS | DPPX Ab IFA, S | No | Yes |
GABCS | GABA-B-R Ab CBA, S | No | Yes |
GD65S | GAD65 Ab Assay, S | Yes | Yes |
GFAIS | GFAP IFA, S | No | Yes |
LG1CS | LGI1-IgG CBA, S | No | Yes |
GL1IS | mGluR1 Ab IFA, S | No | Yes |
NMDCS | NMDA-R Ab CBA, S | No | Yes |
CCN | N-Type Calcium Channel Ab | No | Yes |
CCPQ | P/Q-Type Calcium Channel Ab | No | Yes |
PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
PCATR | Purkinje Cell Cytoplasmic Ab Type Tr | No | Yes |
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
ARBI | ACh Receptor (Muscle) Binding Ab | Yes | No |
ARMO | ACh Receptor (Muscle) Modulating Ab | No | No |
AGNBS | AGNA-1 Immunoblot, S | No | No |
AMPIS | AMPA-R Ab IF Titer Assay, S | No | No |
AMIBS | Amphiphysin Immunoblot, S | No | No |
AN1BS | ANNA-1 Immunoblot, S | No | No |
AN2BS | ANNA-2 Immunoblot, S | No | No |
CRMWS | CRMP-5-IgG Western Blot, S | Yes | No |
DPPCS | DPPX Ab CBA, S | No | No |
DPPTS | DPPX Ab IFA Titer, S | No | No |
GABIS | GABA-B-R Ab IF Titer Assay, S | No | No |
GFACS | GFAP CBA, S | No | No |
GFATS | GFAP IFA Titer, S | No | No |
GL1CS | mGluR1 Ab CBA, S | No | No |
GL1TS | mGluR1 Ab IFA Titer, S | No | No |
NMDIS | NMDA-R Ab IF Titer Assay, S | No | No |
PC1BS | PCA-1 Immunoblot, S | No | No |
PCTBS | PCA-Tr Immunoblot, S | No | No |
PCABP | Purkinje Cell Cytoplasmic Ab Type 1 | No | No |
If client requests or if indirect immunofluorescence assay (IFA) patterns suggest collapsin response-mediator protein-5-IgG (CRMP-5-IgG), then CRMP-5-IgG Western blot, acetylcholine receptor muscle binding, and acetylcholine muscle modulating antibody are performed at an additional charge.
If IFA patterns suggest amphiphysin antibody, then amphiphysin immunoblot is performed at an additional charge.
If IFA pattern suggests AGNA-1 antibody, then AGNA-1 immunoblot is performed at an additional charge.
If IFA pattern suggests ANNA-1 antibody, then ANNA-1 immunoblot is performed at an additional charge.
If IFA pattern suggests ANNA-2 antibody, then ANNA-2 immunoblot is performed at an additional charge.
If IFA pattern suggests PCA-1 antibody, then PCA-1 immunoblot is performed at an additional charge.
If IFA pattern suggests PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge.
If IFA pattern suggests AMPA-receptor antibody, and AMPA-receptor antibody cell-binding assay (CBA) is positive, then AMPA-receptor antibody IF titer assay is performed at an additional charge.
If AMPA-receptor antibody CBA is positive, then CRMP-5-IgG Western blot, ACh receptor (muscle) binding antibody, and ACh receptor (muscle) modulating antibody are performed at an additional charge.
If CASPR2-receptor antibody CBA is positive, then CRMP-5-IgG Western blot, ACh receptor (muscle) binding antibody, and ACh receptor (muscle) modulating antibody are performed at an additional charge.
If IFA pattern suggests GABA-B-receptor antibody, and GABA-B-receptor antibody is positive, then GABA-B-receptor antibody IF titer assay is performed at an additional charge.
If IFA pattern suggests GFAP antibody, then GFAP IFA titer and GFAP CBA are performed at an additional charge.
If IFA pattern suggests NMDA-receptor antibody, and NMDA-receptor antibody CBA is positive, then NMDA-receptor antibody IF titer assay is performed at an additional charge.
If IFA patterns suggest PCA-1, then Purkinje cell cytoplasmic antibody type 1 assay is performed at an additional charge.
See Epilepsy Autoimmune Evaluation Algorithm, Serum in Special Instructions.
AGN1S, AMPHS, AMPIS, ANN1S, ANN2S, ANN3S, CRMS, DPPIS, DPPTS, GABIS, GFAIS, GFATS, GL1IS, GL1TS, NMDIS, PCAB2, PCABP, PCATR: Indirect Immunofluorescence Assay (IFA)
AMPCS, CS2CS, DPPCS, GABCS, GFACS, GL1CS, LG1CS, NMDCS: Cell Binding Assay (CBA)
CRMWS: Western Blot (WB)
AGNBS, AMIBS, AN1BS, AN2BS, PC1BS, PCTBS: Immunoblot (IB)
ARBI, CCN, CCPQ, GANG, GD65S: Radioimmunoassay (RIA)
ARMO: Live Cell Assay (LCA)